The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt ...
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over. Tirzepatide includes blockbuster ...
After a second investigation, the FDA announced tirzepatide will no longer be on the agency’s drug shortage list. Dates were announced for distribution of compounded forms for the drugs to end.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback